|
Saturday, 17 September 2011 01:29 |
|
BioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced today the last visit of the last subject and preliminary results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.
|
|
Read more...
|
|
Saturday, 17 September 2011 01:25 |
|
Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist.
|
|
Read more...
|
|
Friday, 16 September 2011 16:43 |
|
Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced that an independent Data Safety Monitoring Board (DSMB) recently completed a pre-specified interim analysis for safety and futility for Soligenix's confirmatory Phase 3 clinical trial of orBec® an oral formulation of beclomethasone dipropionate (BDP) in acute gastrointestinal Graft-versus-Host disease (GI GVHD).
|
|
Read more...
|
|
Friday, 16 September 2011 16:38 |
|
ChemoCentryx, Inc. today announced that the Company's novel, orally active CCR2 antagonist, CCX140-B, demonstrated an excellent safety profile and exhibited clear signs of biological and clinical effect in a Phase II study in patients with type 2 diabetes on stable doses of metformin.
|
|
Read more...
|
|
Thursday, 15 September 2011 00:25 |
|
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
|
|
Read more...
|
|
Thursday, 15 September 2011 00:22 |
|
Aeterna Zentaris Inc. (the "Company") earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.
|
|
Read more...
|
|
Wednesday, 14 September 2011 01:33 |
|
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic melanoma, an invasive skin cancer of bad prognosis.
|
|
Read more...
|
|
Wednesday, 14 September 2011 01:25 |
|
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids.
|
|
Read more...
|
|
Tuesday, 13 September 2011 00:58 |
|
Alchemia Limited (ASX:ACL), today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC).
|
|
Read more...
|
|
Tuesday, 13 September 2011 00:55 |
|
Oncothyreon Inc. (Nasdaq: ONTY) announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer.
|
|
Read more...
|
|
|
Saturday, 17 September 2011 01:27 |
|
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.
|
|
Read more...
|
|
Friday, 16 September 2011 16:45 |
|
Detroit Medical Center (DMC) has been selected as the first Detroit area hospital to participate in a pivotal clinical study to evaluate the safety and effectiveness of a new therapy for patients with moderate to severe obstructive sleep apnea (OSA).
|
|
Read more...
|
|
Friday, 16 September 2011 16:39 |
|
Partners Bristol-Myers Squibb and AstraZeneca reported positive data from a Phase IIIb study evaluating the addition of the dipeptidyl peptidase-4 (DPP-4) inhibitor Onglyza™ (saxagliptin) to ongoing insulin therapy (with or without metformin) in adult patients with type II diabetes.
|
|
Read more...
|
|
Thursday, 15 September 2011 00:26 |
|
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent.
|
|
Read more...
|
|
Thursday, 15 September 2011 00:23 |
|
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company’s study of eculizumab (Soliris®) in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.
|
|
Read more...
|
|
Wednesday, 14 September 2011 01:35 |
|
ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II studies with lead product Fibrocaps in surgical hemostasis.
|
|
Read more...
|
|
Wednesday, 14 September 2011 01:25 |
|
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536.
|
|
Read more...
|
|
Wednesday, 14 September 2011 01:12 |
|
ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme's Enhanze™ technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), in subjects with hereditary angioedema (HAE).
|
|
Read more...
|
|
Tuesday, 13 September 2011 00:55 |
|
HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.
|
|
Read more...
|
|
Tuesday, 13 September 2011 00:53 |
|
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON™ (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments.
|
|
Read more...
|
|
